CONTACT US

Circa Group Pty Ltd
Bio21 Molecular Science
& Biotechnology Institute
30 Flemington Road, Parkville
VIC 3010 Australia
Twitter @circagroup

Tony Duncan
Chief Executive Officer
Tony.Duncan@circagroup.com.au

Warwick Raverty
Chief Scientist
Warwick.Raverty@circagroup.com.au

c/o Bio 21, Flemington Road
Melbourne
Australia

+61 419 303 117

Circa Group is converting waste biomass into advanced biochemical materials.

News

CIRCA GROUP AND SANOOSA SIGN MOU TO FOCUS ON CANCER MOLECULE

Simm Design

MELBOURNE, AUSTRALIA – 13 September 2017 – Biotechnology companies Circa Group Pty. Ltd. and Sanoosa Pty. Ltd. have signed a Memorandum of Understanding (MoU) to continue developing molecules showing early-stage promise in inhibiting protein-protein interactions, which play a key role in disease development.
 
Targeting such protein complexes directly allows for a more specific response and attacks early disease promoting events. 
 
Circa and Sanoosa have been developing specific molecules for protein-protein interaction inhibition for three years. The MoU commits the companies to collaborate for a further year, allowing them to build on existing research.
 
Dr. Warwick Raverty, Chief Scientist at Circa Group, said, “This MoU has been agreed due to recent promising signs of the molecule’s performance against this specific target protein, using Sanoosa’s advanced modelling processes and in lab trials.”
 
Dr. Herbert Treutlein and Dr. Wolfgang Kissel, Co-Founders and Directors at Sanoosa, said, “By signing this MoU, we will continue Sanoosa’s strategy of working on difficult-to-drug targets, using both our accelerated computational molecule discovery and design capabilities.”